Browsing by Author "Almeida, L."
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional StudyPublication . Reis, A.; Santos, M.; Vicente, M.; Furtado, I.; Cruz, C.; Melo, A.; Carvalho, L.; Gonçalves, F.; Sa-Couto, P.; Almeida, L.BACKGROUND: Health-related quality of life (HRQoL) impairment is common in pulmonary hypertension (PH), but its clinical predictors are not well established. This study aims to characterize the HRQoL of patients with pulmonary arterial hypertension (PAH) and other precapillary forms of PH (pcPH) and to explore its clinical correlates. MATERIALS AND METHODS: A cross-sectional, observational study of patients with documented PAH and other forms of pcPH. Patients completed two patient-reported outcome measures (PROM): Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and Nottingham Health Profile (NHP). Clinical characteristics were retrieved from electronic medical records. RESULTS: Mean CAMPHOR and NHP scores for the study population were indicative of a moderate HRQoL impairment. Patients in World Health Organisation Functional Classes (WHO FC) III/IV showed significantly worse HRQoL. The main clinical correlates of HRQoL were WHO FC, 6-minute walking distance (6MWD), and Borg dyspnoea index. Overall quality of life (QoL), assessed through CAMPHOR's QoL domain, showed patterns comparable to HRQoL measured by both instruments. CONCLUSIONS: HRQoL, measured by two different PROMs, is impaired in Portuguese patients with PAH and other forms of pcPH, particularly in patients with increased disease severity. WHO FC, 6MWD, and Borg dyspnoea index are highly correlated with HRQoL and QoL.
- Investigação Bioquímica e Molecular na Morte Súbita do Lactente (SIDS)Publication . Cardoso, M.; Pinheiro, J.; Pereira, C.; Sousa, C.; Nogueira, C.; Tesa, A.; Ramos, A.; Balreira, A.; Lima, C.; Valongo, C.; Couto, D.; Quelhas, D.; Fonseca, H.; Rocha, H.; Almeida, L.; Rodrigues, R.; Santos, R.; Santorelli, F.; Vilarinho, L.RESUMO SIDS (Sudden Infant Death Syndrome) é a designação utilizada para definir a morte súbita do lactente, que permanece inexplicada após uma cuidadosa investigação do caso, a qual incluí a realização de autópsia, o exame do local da morte e a análise da história clínica. Devido à rápida deterioração que provocam, as doenças metabólicas constituem potenciais causas de morte súbita, quer pelas crises que ocasionam com intoxicação e comprometimento da sobrevivência do indivíduo, quer por provocarem alterações que aumentam o risco de falência de determinados orgãos. Objectivos: Com este trabalho pretendemos avaliar o contributo relativo das doenças metabólicas e dos défices energéticos nas situações de morte súbita e inexplicada do lactente, na população portuguesa. Pacientes e Métodos: Foram disponibilizadas para investigação amostras biológicas congeladas de 51 lactentes cuja causa de morte era desconhecida. Os produtos foram colhidos durante a autópsia e incluíram: soro, urina, humor vítreo, músculo e fígado. Nos fluídos biológicos fez-se o estudo dos aminoácidos e dos ácidos orgânicos e nos tecidos sólidos o doseamento da actividade dos vários complexos da cadeia respiratória mitocondrial e do teor em glicogénio. Foi ainda efectuada a extracção de DNA total a partir dos tecidos sólidos acima referidos o qual foi utilizado para estudos moleculares. Resultados: Foi possível identificar através dos estudos moleculares um caso de intolerância hereditária à frutose - HFI (homozigotia para a mutação A149P no gene ALDOB). Nos estudos bioquímicos foi encontrado um caso positivo de very long-chain acyl-CoA dehydrogenase - VLCAD e na maioria das determinações efectuadas, desvios em relação aos controlos normais inerentes ao catabolismo e aos processos de cadaverização, sendo de salientar: valores muito elevados dos aminoácidos séricos e a presença sistemática de grande quantidade de ácido láctico na urina. Conclusões: Nas doenças metabólicas o risco de recorrência existe e a identificação de um caso classificado como SIDS, como sendo na realidade um erro inato do metabolismo, é importante para a família, quer em termos de instituição de tratamento adequado e adopção de medidas preventivas, quer em termos de aconselhamento genético. ABSTRACT SIDS (Sudden Infant Death Syndrome) is the sudden and unexpected death including performance of a complete autopsy, examination of death scene, and review of clinical history. Metabolic disorders can lead to sudden dead because they cause crises of intoxication and life threatening, with dysfunction of several organs, that raise the risk of general failure. Objectives: Our main objective with this study, was to evaluate the significance of metabolic disorders and energy deficiencies in sudden infant death syndrome, in Portuguese population. Patients and Methods: We got biological frozen samples from 51 children whose cause of dead was unknown. The products were collected during autopsy and included: serum, urine, humour vitreous, muscle and liver. In the biological fluids samples we analysed amino acids as well as organic acids, and in referred tissues we determinate the activity of the respiratory chain complexes and the amount of glycogen. It was also possible to get total DNA from solid tissues which was used for molecular studies. Results: Based on molecular findings, it was possible to identify one case of fructose intolerance - HFI (patient homozygous for A149P in ALDOB gene). Biochemical studies revealed one case of very long-chain acyl-CoA dehydrogenase - VLCAD deficiency. However, in the majority of the assays performed deviations from normal controls were found, due to catabolism post-morten (plasmatic increase of amino acids and high excretion of lactic acid in urine). Conclusions: In metabolic disorders the risk of recurrence exists. The misdiagnosed inherited errors of metabolism as SIDS, it is important for the family, in terms of treatment, prevention attitude and genetic counselling. of an infant which remains unexplained
- Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnairePublication . Reis, A.; Twiss, J.; Vicente, M.; Gonçalves, F.; Carvalho, L.; Meireles, J.; Melo, A.; McKenna, S.; Almeida, L.BACKGROUND: Patients with pulmonary arterial hypertension (PAH) and other forms of precapillary pulmonary hypertension (PH) have impaired quality of life (QoL). The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a PH-specific patient-reported outcome measure that assesses symptoms, activity limitations and QoL. It was originally developed in UK-English. The main objective of this study was to create an adaptation of the CAMPHOR suitable for a Portuguese-speaking population. METHODS: A multi-step approach was followed: bilingual and lay panel translation; cognitive debriefing interviews; and psychometric testing in repeated postal surveys (2 weeks apart) including assessment of internal consistency, reproducibility and validity. The Nottingham Health Profile (NHP) questionnaire was used as a comparator instrument to test convergent validity. RESULTS: The CAMPHOR was translated without difficulty by the two panels. Cognitive debriefing interviews showed the questionnaire was easily understood and considered relevant to patients' experience with their illness. Psychometric evaluation was performed with 50 PAH patients (47 ± 14 years, 37 women). Cronbach's alpha coefficients showed good internal consistency for the three CAMPHOR scales [Symptoms = 0.95; Activities = 0.93 and QoL = 0.94]. Test-retest coefficients showed that all scales had excellent reliability (Symptoms = 0.94; Activities = 0.89 and QoL = 0.93), indicating low levels of random measurement error. The CAMPHOR correlated as expected with the NHP. The magnitude of correlations followed a similar pattern to those in the original development study. The CAMPHOR also exhibited evidence of known group validity in its ability to distinguish between self-reported severity and general health groups. CONCLUSIONS: A valid and reliable version of the CAMPHOR questionnaire for the European Portuguese-speaking population was developed and is recommended for use.
- A Prediction Rule to Stratify Mortality Risk of Patients with Pulmonary TuberculosisPublication . Bastos, H.; Osório, N.; Castro, A.; Ramos, A.; Carvalho, T.; Meira, L.; Araújo, D.; Almeida, L.; Boaventura, R.; Fragata, P.; Chaves, C.; Costa, P.; Portela, M.; Ferreira, I.; Magalhães, S.; Rodrigues, F.; Sarmento-Castro, R.; Duarte, R.; Guimarães, J.; Saraiva, M.Tuberculosis imposes high human and economic tolls, including in Europe. This study was conducted to develop a severity assessment tool for stratifying mortality risk in pulmonary tuberculosis (PTB) patients. A derivation cohort of 681 PTB cases was retrospectively reviewed to generate a model based on multiple logistic regression analysis of prognostic variables with 6-month mortality as the outcome measure. A clinical scoring system was developed and tested against a validation cohort of 103 patients. Five risk features were selected for the prediction model: hypoxemic respiratory failure (OR 4.7, 95% CI 2.8-7.9), age ≥50 years (OR 2.9, 95% CI 1.7-4.8), bilateral lung involvement (OR 2.5, 95% CI 1.4-4.4), ≥1 significant comorbidity-HIV infection, diabetes mellitus, liver failure or cirrhosis, congestive heart failure and chronic respiratory disease-(OR 2.3, 95% CI 1.3-3.8), and hemoglobin <12 g/dL (OR 1.8, 95% CI 1.1-3.1). A tuberculosis risk assessment tool (TReAT) was developed, stratifying patients with low (score ≤2), moderate (score 3-5) and high (score ≥6) mortality risk. The mortality associated with each group was 2.9%, 22.9% and 53.9%, respectively. The model performed equally well in the validation cohort. We provide a new, easy-to-use clinical scoring system to identify PTB patients with high-mortality risk in settings with good healthcare access, helping clinicians to decide which patients are in need of closer medical care during treatment.
- The Portuguese Severe Asthma Registry: Development, Features, and Data Sharing PoliciesPublication . Sá-Sousa, A.; Fonseca, J.; Pereira, A.; Ferreira, A.; Arrobas, A.; Mendes, A.; Drummond, M.; Videira, W.; Costa, T.; Farinha, P.; Soares, J.; Rocha, P.; Todo-Bom, A.; Sokolova, A.; Costa, A.; Fernandes, B.; Chaves Loureiro, C.; Longo, C.; Pardal, C.; Costa, C.; Cruz, C.; Loureiro, C.; Lopes, C.; Mesquita, D.; Faria, E.; Magalhães, E.; Menezes, F.; Todo-Bom, F.; Carvalho, F.; Regateiro, F.; Falcao, H.; Fernandes, I.; Gaspar-Marques, J.; Viana, J.; Ferreira, J.; Silva, J.; Simão, L.; Almeida, L.; Fernandes, L.; Ferreira, L.; van Zeller, M.; Quaresma, M.; Castanho, M.; André, N.; Cortesão, N.; Leiria-Pinto, P.; Pinto, P.; Rosa, P.; Carreiro-Martins, P.; Gerardo, R.; Silva, R.; Lucas, S.; Almeida, T.; Calvo, T.The Portuguese Severe Asthma Registry (Registo de Asma Grave Portugal, RAG) was developed by an open collaborative network of asthma specialists. RAG collects data from adults and pediatric severe asthma patients that despite treatment optimization and adequate management of comorbidities require step 4/5 treatment according to GINA recommendations. In this paper, we describe the development and implementation of RAG, its features, and data sharing policies. The contents and structure of RAG were defined in a multistep consensus process. A pilot version was pretested and iteratively improved. The selection of data elements for RAG considered other severe asthma registries, aiming at characterizing the patient's clinical status whilst avoiding overloading the standard workflow of the clinical appointment. Features of RAG include automatic assessment of eligibility, easy data input, and exportable data in natural language that can be pasted directly in patients' electronic health record and security features to enable data sharing (among researchers and with other international databases) without compromising patients' confidentiality. RAG is a national web-based disease registry of severe asthma patients, available at asmagrave.pt. It allows prospective clinical data collection, promotes standardized care and collaborative clinical research, and may contribute to inform evidence-based healthcare policies for severe asthma.